Testing a new drug for cancer-related belly fluid
Part of Cancer, Digestive system clinical trials.
This early-phase trial tests an experimental drug called GK02 for people with advanced cancer who have fluid buildup in the belly (malignant ascites). The drug is given directly into the belly to try to reduce the fluid and control symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid tumors (like stomach, colon, pancreatic, or ovarian cancer) that have not responded to at least two prior treatments.
- You have a build-up of fluid in your belly (malignant ascites) that your doctor says needs to be drained.
- You are between 18 and 75 years old.
- You are in generally good health, able to take care of yourself (ECOG score 0-2), and your organs are working well enough.
- You have not had treatment for the fluid in your belly in the past 14 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of therapy where special cells (called SK-NK cells) are injected directly into the belly to treat fluid buildup (ascites) caused by advanced ovarian cancer. It is for patients whose cancer has not responded to at least two prior treatments and who have no other standard options left.
This trial tests a new drug called GK01 in patients with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, and may be an option for those who can have a tumor surgically removed.
This study tests an experimental drug called GO321 in people with advanced solid tumors that have stopped responding to standard treatments or for which no standard treatment exists. The drug is given either as an injection into the tumor or into the abdomen to treat fluid buildup caused by cancer (malignant ascites). This trial aims to see if GO321 is safe and effective.
This Phase 1 study tests SKB315 to treat advanced solid tumors, with special focus on stomach/gastroesophageal junction cancer that has high CLDN18.2 in tumor tissue. It may help you if standard treatments have not worked or are not available, though early-phase studies mainly look at safety and the best way to dose.
This trial tests a new drug called CT0494BCP for advanced stomach cancer that has not responded to previous treatments. The drug targets a protein called CLDN18.2, which is found on many stomach cancer cells, and aims to help your immune system fight the cancer.
This study tests an investigational cell therapy (GK01) for people with advanced solid tumors that have grown despite standard treatment or have no standard treatment option. It may help shrink tumors or slow their growth.
Hear when a new Malignant Ascites Caused by Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.